Abstract

Fluorizoline is a prohibitin-binding compound that triggers apoptosis in several cell lines from murine and human origin, as well as in primary cells from hematologic malignancies by inducing the integrated stress response and ER stress. Recently, it was described that PHB (Prohibitin) 1 and 2 are crucial mitophagy receptors involved in mediating the autophagic degradation of mitochondria. We measured mitophagy in HeLa cells expressing Parkin and in A549, a lung cancer cell line that can undergo mitophagy in a Parkin-independent manner, and we demonstrated that both fluorizoline and rocaglamide A, another PHB-binding molecule, inhibit CCCP- and OA-induced mitophagy. Moreover, we demonstrated that PHBs are mediating Parkin-dependent mitophagy. In conclusion, besides being a potent pro-apoptotic compound, we present fluorizoline as a promising new mitophagy modulator that could be used as anticancer agent.

Details

Title
The prohibitin-binding compound fluorizoline inhibits mitophagy in cancer cells
Author
Núñez-Vázquez, Sonia 1 ; Saura-Esteller José 2 ; Sánchez-Vera, Ismael 2 ; Guilbaud, Emma 3 ; Cosialls, Ana M 2 ; Pons, Gabriel 2 ; Ricci Jean-Ehrland 3   VIAFID ORCID Logo  ; Iglesias-Serret, Daniel 4 ; Marchetti Sandrine 3 ; Gil, Joan 2   VIAFID ORCID Logo 

 Universitat de Barcelona, Oncobell-IDIBELL (Institut d’Investigació Biomèdica de Bellvitge), L’Hospitalet de Llobregat, Departament de Ciències Fisiològiques, Facultat de Medicina i Ciències de la Salut, Barcelona, Spain (GRID:grid.5841.8) (ISNI:0000 0004 1937 0247); Université Côte d’Azur, INSERM, Nice, France (GRID:grid.460782.f) (ISNI:0000 0004 4910 6551); Equipe labellisée Ligue Contre le Cancer, Nice, France (GRID:grid.460782.f) 
 Universitat de Barcelona, Oncobell-IDIBELL (Institut d’Investigació Biomèdica de Bellvitge), L’Hospitalet de Llobregat, Departament de Ciències Fisiològiques, Facultat de Medicina i Ciències de la Salut, Barcelona, Spain (GRID:grid.5841.8) (ISNI:0000 0004 1937 0247) 
 Université Côte d’Azur, INSERM, Nice, France (GRID:grid.460782.f) (ISNI:0000 0004 4910 6551); Equipe labellisée Ligue Contre le Cancer, Nice, France (GRID:grid.460782.f) 
 Universitat de Barcelona, Oncobell-IDIBELL (Institut d’Investigació Biomèdica de Bellvitge), L’Hospitalet de Llobregat, Departament de Ciències Fisiològiques, Facultat de Medicina i Ciències de la Salut, Barcelona, Spain (GRID:grid.5841.8) (ISNI:0000 0004 1937 0247); Universitat de Vic–Universitat Central de Catalunya (UVic- UCC), Vic, Facultat de Medicina, Barcelona, Spain (GRID:grid.440820.a) 
Publication year
2021
Publication date
Sep 2021
Publisher
Nature Publishing Group
e-ISSN
21579024
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2576738038
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.